Liu S, et al. IMPOWER 133: Primary PFS, OS and Safety in a PH1/3 Study of 1L Atezolizumab + Carboplatin + Etoposide in Extensive-Stage SCLC. IASLC 2018, abstract PL02.07.
Sotorasib plus panitumumab bij refractair colorectaal carcinoom met KRAS G12C-mutatie
dec 2023 | Maag-darm-leveroncologie